EUnetHTA 21 Publication of Second Joint Clinical Assessment: Introducing the Evoke Spinal Cord Stimulation

By HEOR Staff Writer

July 21, 2023

 EUnetHTA 21 has published their second Joint Clinical Assessment on the Evoke Spinal Cord Stimulation (SCS) System. This advanced device utilizes Evoked Compound Action Potentials (ECAPs) to guide programming of stimulation parameters and provide real-time, closed-loop stimulation. This unique feature allows the Evoke System to adjust the stimulation output level for every pulse, maintaining the ECAP near the target amplitude. This stands in contrast to other commercially available SCS devices which do not employ spinal cord feedback to adjust stimulation. 

The Evoke SCS is indicated for the treatment of chronic, intractable pain in the trunk and/or limbs. Chronic pain, unlike acute pain, persists long after the initial injury or illness has healed. The Evoke System is primarily used to treat chronic neuropathic, mixed neuropathic/nociceptive, or ischemic pain, all of which are caused by nervous system damage or dysfunction. 

This system is designed for patients with chronic, intractable pain who are not contraindicated for the system. It represents a new generation of SCS because of its ECAP-guided programming, an enhancement to other available SCS systems. 

Promising study results suggest that the Evoke System is comparable or superior to other treatments reported in literature. Clinical data from prospective investigations of the Evoke System support its safety and performance. The anticipated benefits of the Evoke System outweigh the risks, providing a compelling case for its use in treating chronic, intractable pain.

Reference url

Recent Posts

Navigating Novo Nordisk Board Changes: Leadership for Growth and Strategy

By João L. Carapinha

October 21, 2025

The Novo Nordisk board changes involve a major restructuring, as the Novo Nordisk Foundation is revitalizing leadership ahead of a general meeting on November 14, 2025, where new directors will be elected. Key candidates include former CEO Lars Rebien Sørensen as chair and Cees de Jong as vice ch...
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC

By João L. Carapinha

October 20, 2025

If you're searching for effective options in Keytruda lung cancer treatment, recent data shows pembrolizumab (Keytruda) significantly boosts survival rates in non-small cell lung cancer (NSCLC). In the KEYNOTE-671 trial, this immunotherapy combined with chemotherapy raised five-year overall survi...
Cabotegravir HIV Prevention: First Injectable PrEP Recommended for High-Risk Groups

By HEOR Staff Writer

October 17, 2025

Cabotegravir HIV prevention is now officially recommended in the UK for adults and young people at high risk of HIV who cannot take daily oral PrEP. What makes this approval so significant? For those unable to adhere to daily medication, cabotegravir provides a bi-monthly injectable alternative w...